1316/75

FORM D

Cr3 grait ਼ੀਖ਼ੀ Processing Section

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

SEP 12 2008

FORM D

Washington, DC TŪ3

NOTICE OF SALE OF SECURITIES PURSUANT TO REGULATION D, **SECTION 4(6), AND/OR** UNIFORM LIMITED OFFERING EXEMPTION

OMB APPROVAL						
OMB Number:	3235-0076					
Expires: August	31,2008					
Estimated average	burden					
hours per response	16.00					

SEC USE ONLY								
Prefix	Serial							
DA	TE RECEIVI	ED						

Name of Offering (check if this is an amendment and name has changed, and indicate change.)	
Preferred Stock and warrants to purchase common stock	
Filing Under (Check box(es) that apply): Rule 504 Rule 505 Rule 506 Section 4(6	i) ULOE
Type of Filing:	
A. BASIC IDENTIFICATION DATA	
1. Enter the information requested about the issuer	
Name of Issuer (check if this is an amendment and name has changed, and indicate change.)	08059289
Anthera Pharmaceuticals, Inc.	
Address of Executive Offices (Number and Street, City, State, Zip Code)	Telephone Number (Including Area Code)
1900 South Norfolk Street, Suite 260, San Mateo, CA 94403	(650) 931–8868
Address of Principal Business Operations (Number and Street, City, State, Zip Code) (if different from Executive Offices)	Telephone Number (Including Area Code)
Brief Description of Business	
Biopharmaceutical company focused on the development and commercialization of novel t medical needs.	herapeutics to treat serious diseases with unmet
Type of Business Organization	(please specify): PROCESSED
	(please specify): PROCESSED
business trust limited partnership, to be formed	─────────────────────────────────────
Month Year Actual or Estimated Date of Incorporation or Organization: 0 9 0 4 ✓ Actual Est	\ <u>-</u> - · · · · · · · · · · · · · · · · · ·
Jurisdiction of Incorporation or Organization: (Enter two-letter U.S. Postal Service abbreviation for Sta	
CN for Canada; FN for other foreign jurisdiction)	DE IIIOMOON REGIERO
GENERAL INSTRUCTIONS	
Federal: Who Must File: All issuers making an offering of securities in reliance on an exemption under Regulation D 77d(6).	O or Section 4(6), 17 CFR 230.501 et seq. or 15 U.S.C.
When To File: A notice must be filed no later than 15 days after the first sale of securities in the offerin and Exchange Commission (SEC) on the earlier of the date it is received by the SEC at the address given which it is due, on the date it was mailed by United States registered or certified mail to that address.	g. A notice is deemed filed with the U.S. Securities below or, if received at that address after the date on
Where To File: U.S. Securities and Exchange Commission, 450 Fifth Street, N.W., Washington, D.C. 2	20549.
Copies Required: Five (5) copies of this notice must be filed with the SEC, one of which must be manual photocopies of the manually signed copy or bear typed or printed signatures.	ally signed. Any copies not manually signed must be
Information Required: A new filing must contain all information requested. Amendments need only repthereto, the information requested in Part C, and any material changes from the information previously supnot be filed with the SEC.	port the name of the issuer and offering, any changes iplied in Parts A and B. Part E and the Appendix need
Filing Fee: There is no federal filing fee.	
State: This notice shall be used to indicate reliance on the Uniform Limited Offering Exemption (ULOE) for ULOE and that have adopted this form. Issuers relying on ULOE must file a separate notice with the are to be, or have been made. If a state requires the payment of a fee as a precondition to the claim accompany this form. This notice shall be filed in the appropriate states in accordance with state law this notice and must be completed.	e Securities Administrator in each state where sales for the exemption, a fee in the proper amount shall
ATTENTION —	
Failure to file notice in the appropriate states will not result in a loss of the federal appropriate federal notice will not result in a loss of an available state exemption un filing of a federal notice	exemption. Conversely, failure to file the less such exemption is predictated on the

Comment of the Commen	A. BAŠIC IĎI	NTIFICATION DATA		The state of the s
2. Enter the information requested for the fo	ollowing:		, , , , , , , , , , , , , , , , , , ,	
• Each promoter of the issuer, if the is	ssuer has been organized w	ithin the past five years;		
Each beneficial owner having the port	wer to vote or dispose, or dis	ect the vote or disposition o	of, 10% or more of a	a class of equity securities of the issuer.
Each executive officer and director	of corporate issuers and of	corporate general and man	aging partners of p	artnership issuers; and
 Each general and managing partner 	of partnership issuers.			
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	✓ Director	General and/or Managing Partner
Full Name (Last name first, if individual) Truex, Paul F.				
Business or Residence Address (Number and C/O Anthera Pharmaceuticals, Inc., 1900)			A 94403	
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Lowe, Chris				
Business or Residence Address (Number and C/O Anthera Pharmaceuticals, Inc., 1900		· ·	A 94403	
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Henney, Christopher S.	·····			
Business or Residence Address (Number and	d Street, City, State, Zip Co	ode)		
c/o Anthera Pharmaceuticals, Inc., 1900	South Norfolk Street, S	uite 260, San Mateo, C	A 94403	
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual)			-	
Bianchi, Annette	10. 0. 0. 0. 0.			
Business or Residence Address (Number and 1001 Bayhill Drive, Suite 300, San Brun		ode)		
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Healy, James				
Business or Residence Address (Number and 140 Geary Street, 10th Floor, San France)		ode)		
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer	Director	General and/or Managing Partner
Full Name (Last name first, if individual) Leheny, Rachel		Programme of the second		
Business or Residence Address (Number an 500 Park Avenue, New York, NY 10022	• • • • • • • • • • • • • • • • • • • •	ode)		
Check Box(es) that Apply: Promoter	Beneficial Owner	Executive Officer		General and/or Managing Partner
Full Name (Last name first, if individual) Santel, Donald J.				
Business or Residence Address (Number an c/o Anthera Pharmaceuticals, Inc., 1900	•	-	CA 94403	

A. BASIC IDENTIFICATION DATA 1. Enter the information requested for the following: Each promoter of the issuer, if the issuer has been organized within the past five years; Each beneficial owner having the power to vote or dispose, or direct the vote or disposition of, 10% or more of a class of equity securities of the issuer: Each executive officer and director of corporate issuers and of corporate general and managing partners of partnership issuers; and Each general and managing partner of partnership issuers. Executive Officer Promoter Beneficial Owner Check Box(es) General and/or Managing Partner Director that Apply: Full Name (Last name first, if individual) Thompson, David E. Business or Residence Address (Number and Street, City, State, Zip Code) c/o Anthera Pharmaceuticals, Inc., 1900 South Norfolk Street, Suite 260, San Mateo, CA 94403 Executive Officer Check Box(es) □ Promoter Beneficial Owner Director General and/or Managing Partner that Apply: Full Name (Last name first, if individual) Vantage Point Partners Business or Residence Address (Number and Street, City, State, Zip Code) 1001 Bayhill Drive, Suite 300, San Bruno, CA 94066 Beneficial Owner Executive Officer Check Box(es) Promoter General and/or Managing Partner Director that Apply: Full Name (Last name first, if individual) Sofinnova Venture Partners Business or Residence Address (Number and Street, City, State, Zip Code) 140 Geary Street, 10th Floor, San Francisco, CA 94108 Executive Officer Check Box(es) □ Promoter Beneficial Owner Director General and/or Managing Partner that Apply: Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Beneficial Owner Executive Officer Check Box(es) Promoter that Apply: Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Executive Officer Check Box(es) Promoter Beneficial Owner Director General and/or Managing Partner that Apply: Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Promoter Beneficial Owner Executive Officer Check Box(es) General and/or Managing Partner that Apply: Director Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code) Executive Officer Beneficial Owner □Promoter Check Box(es) that Apply: Director General and/or Managing Partner Full Name (Last name first, if individual) Business or Residence Address (Number and Street, City, State, Zip Code)

	. 4			B. 1	NFORMAŢ	ION ABOU	T _l OFFÈRI	NG ,	100 y	P.	2 3 3 4 5	
1. Has the	e issuer sole	d, or does ti	ne issuer i	ntend to se	ll, to non-a	ccredited i	nvestors in	this offeri	ng?		Yes	No 🔀
					Appendix				-			<u>12</u> 3
2. What i	2. What is the minimum investment that will be accepted from any individual?										\$	
_												No
											_	
4. Enter the information requested for each person who has been or will be paid or given, directly or indirectly, any commission or similar remuneration for solicitation of purchasers in connection with sales of securities in the offering. If a person to be listed is an associated person or agent of a broker or dealer registered with the SEC and/or with a state or states, list the name of the broker or dealer. If more than five (5) persons to be listed are associated persons of such a broker or dealer, you may set forth the information for that broker or dealer only.										:		
Full Name	(Last name	first, if ind	ividual)								-	
Business or	Residence	Address (N	lumber and	Street, C	ity, State, 2	Cip Code)						
Name of As	ssociated B	roker or De	aler									
States in W	hich Persor	Listed Has	Solicited	or Intends	to Solicit	Purchasers	<u> </u>					
(Check	"All State	s" or check	individual	States)			•••••		******		☐ Al	l States
AL IL MT	AK IN NE SC	IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	MS OR WY	MO PA PR
Full Name	(Last name	first, if ind	ividual)					·	•			
Business o	r Residence	Address (1	Number an	d Street, C	City, State,	Zip Code)		· •				
Name of As	ssociated B	roker or De	aler									
States in W												
(Check	"All State	s" or check	individual	States)		i.	•••••••••			***************************************	□ Al	l States
IL MT RI	AK IN NE SC	IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	MO PA PR
Full Name	(Last name	first, if ind	ividual)									
Business o	r Residence	e Address (l	Number an	d Street, C	City, State,	Zip Code)						
Name of As	ssociated B	roker or De	aler								· · · · · · · · · · · · · · · · · · ·	<u>-</u> -
States in W	hich Person	n Listed Ha	s Solicited	or Intends	to Solicit	Purchasers						
(Check	c "All State	s" or check	individual	States)	• • • • • • • • • • • • • • • • • • • •		••••	***************************************	***************************************		☐ Al	l States
AL IL MT RI	AK IN NE SC	AZ IA NV SD	AR KS NH TN	CA KY NJ TX	CO LA NM UT	CT ME NY VT	DE MD NC VA	DC MA ND WA	FL MI OH WV	GA MN OK WI	HI MS OR WY	MO PA PR

C. OFFERING PRICE, NUMBER OF INVESTORS, EXPENSES AND USE OF PROCEEDS

1.	Enter the aggregate offering price of securities included in this offering and the total amount already sold. Enter "0" if the answer is "none" or "zero." If the transaction is an exchange offering, check this box and indicate in the columns below the amounts of the securities offered for exchange and already exchanged.			
	Type of Security	Aggregate Offering Pri		Amount Already Sold
		_		
	Debt			
	Equity	\$ 19,300,63		\$ 19,355,637.94
	Convertible Securities (including warrants) represents aggregate value of the shares of common stock issuable upon exercise of the Warrants Partnership Interests	<u>\$</u> 321,175.9 \$_	92	321,175.92 \$
	Other (Specify)			
	Total			
	Answer also in Appendix, Column 3, if filing under ULOE.			
2 .	Enter the number of accredited and non-accredited investors who have purchased securities in this offering and the aggregate dollar amounts of their purchases. For offerings under Rule 504, indicate the number of persons who have purchased securities and the aggregate dollar amount of their purchases on the total lines. Enter "0" if answer is "none" or "zero."			Aggregate
		Number Investors		Dollar Amount of Purchases
	Accredited Investors			\$ 19,676,813.86
	Non-accredited Investors			\$
	Total (for filings under Rule 504 only)			\$
	Answer also in Appendix, Column 4, if filing under ULOE.			
3.	If this filing is for an offering under Rule 504 or 505, enter the information requested for all securities sold by the issuer, to date, in offerings of the types indicated, in the twelve (12) months prior to the first sale of securities in this offering. Classify securities by type listed in Part C — Question 1.			
		Type of		Dollar Amount
	Type of Offering	Security		Sold
	Rule 505			\$
	Regulation A			\$
	Rule 504			\$
	Total			\$_0.00
4	a. Furnish a statement of all expenses in connection with the issuance and distribution of the securities in this offering. Exclude amounts relating solely to organization expenses of the insurer. The information may be given as subject to future contingencies. If the amount of an expenditure is not known, furnish an estimate and check the box to the left of the estimate.			
	Transfer Agent's Fees			\$
	Printing and Engraving Costs	************		\$
	Legal Fees		Z	\$ 20,000.00
	Accounting Fees			\$
	Engineering Fees		П	s
	Sales Commissions (specify finders' fees separately)			s
	Other Expenses (identify)			s
	Total			\$ 20,000.00

	C. OFFERING PRICE, N	JMBER OF INVESTORS, EXPENSES AND	USE OF PROCEEDS	
	b. Enter the difference between the aggregate o and total expenses furnished in response to Part C proceeds to the issuer."		sted gross	19,656,813.86
5.	Indicate below the amount of the adjusted gross each of the purposes shown. If the amount for check the box to the left of the estimate. The total proceeds to the issuer set forth in response to 1	any purpose is not known, furnish an esti- al of the payments listed must equal the adjus	mate and	
			Payments to Officers, Directors, & Affiliates	Payments to Others
	Salaries and fees			. D\$
	Purchase of real estate		\$. 🗆 \$
	Purchase, rental or leasing and installation of	machinery		□ •
	and equipment			_
	Construction or leasing of plant buildings and		[] \$. L 3———
	Acquisition of other businesses (including the offering that may be used in exchange for the issuer pursuant to a merger)	assets or securities of another	\\ \$	□\$
	Repayment of indebtedness			
	Working capital			F 19,656,813.80
	Other (specify):			\$
				m s
	Column Totals			
	Total Payments Listed (column totals added) .		§ <u>1</u>	9,656,813.86
		D. FEDERAL SIGNATURE		
sig	e issuer has duly caused this notice to be signed by nature constitutes an undertaking by the issuer to information furnished by the issuer to any non-	furnish to the U.S. Securives and Exchang	e Commission, upon writte	ule 505, the following en request of its staff,
İss	uer (Print or Type)	Signature	Date	
	thera Pharmaceuticals, Inc.	1 they	September <u>3</u> ,	2008
Na	me of Signer (Print or Type)	Title of Signer (Print of Type)		
		President and Chief Executive Office		

- ATTENTION ----

Intentional misstatements or omissions of fact constitute federal criminal violations. (See 18 U.S.C. 1001.)

12.7		E. STATE SIGNATURE									
1.	Is any party described in 17 CFR	230.262 presently subject to any of the disquali	fication Yes No								
		See Appendix, Column 5, for state respon	nse.								
2.	 The undersigned issuer hereby undertakes to furnish to any state administrator of any state in which this notice is filed a notice on Form D (17 CFR 239.500) at such times as required by state law. 										
3.	3. The undersigned issuer hereby undertakes to furnish to the state administrators, upon written request, information furnished issuer to offerees.										
4. The undersigned issuer represents that the issuer is familiar with the conditions that must be satisfied to be entitled to the limited Offering Exemption (ULOE) of the state in which this notice is filed and understands that the issuer claiming the available of this exemption has the burden of establishing that these conditions have been satisfied.											
	uer has read this notification and know thorized person.	vs the contents to be true and has duly caused this	notice to be signed on its behalf by the undersigned								
Issuer (Print or Type)	Signature	Date								
Anthera	a Pharmaceuticals, Inc.	IF/W	September. <u>3</u> , 2008								
Name (Print or Type)	Title (Print of Type)									

President and Chief Executive Officer

Instruction:

Paul E. Truex

Print the name and title of the signing representative under his signature for the state portion of this form. One copy of every notice on Form D must be manually signed. Any copies not manually signed must be photocopies of the manually signed copy or bear typed or printed signatures.

APPENDIX 2 3 4 1 Disqualification under State ULOE Type of security and aggregate (if yes, attach Intend to sell Type of investor and explanation of to non-accredited offering price amount purchased in State waiver granted) offered in state investors in State (Part E-Item 1) (Part C-Item 1) (Part C-Item 2) (Part B-Item 1) Number of Number of Preferred Stock Accredited Non-Accredited and Warrants Investors Yes No State Yes No Investors Amount Amount ALAKAZAR \$10,446,935.63 4 \$10,446,935 0 \$0.00 X CA CO CT DE DC FL GA Н ID IL IN IA KS KY LA ME MD MA MI MN MS

APPENDIX									
1	Intend to non-a investor	to sell ccredited s in State -Item 1)	Type of security and aggregate offering price offered in state (Part C-Item 1)		4			5 Disqualification under State ULOE (if yes, attach explanation of waiver granted) (Part E-Item 1)	
State	Yes	No	Preferred Stock and Warrants	Number of Accredited Investors	Amount	Number of Non-Accredited Investors	Amount	Yes	No
МО									
MT									
NE							-		
NV									
NH									
NJ							· · · · · · · · · · · · · · · · · · ·		
NM									
NY		×	\$4,263,133.15	2	\$4,263,133.	0	\$0.00		X
NC		×	\$1,306,154.63	2	\$1,306,154.	0	\$0.00		×
ND									
ОН					<u> </u>				
ОК									
OR									
PA									
RI							- · · · <u>-</u>		
SC					·				
SD									
TN									
TX									
UT									
VT									
VA						_			
WA									
wv									
WI									

